Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 6, 2014, Pages 2501-2504

  Bozkurt, Oktay ^a   Berk, Veli ^a   Kaplan, Muhammed Ali ^b   Cetin, Bulent ^c   Ozaslan, Ersin ^a   Karaca, Halit ^a   Inanc, Mevlude ^a   Duran, Ayse Ocak ^a   Ozkan, Metin ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Breast cancer; Capecitabine; Mean corpuscular volume; Prognostic factor

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; FLUOROURACIL; TUMOR MARKER;

ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; MEAN CORPUSCULAR VOLUME; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DEOXYCYTIDINE; ERYTHROCYTE INDICES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84899804504     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.6.2501     Document Type: Article

References (22)

1. Allegra C (2002). Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol, 20, 1711-3.
2. Arslan C, Aksoy S, Dizdar O, et al (2011). Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response. Tumori, 97, 711-6.
3. Budman DR (2000). Capecitabine. Invest New Drugs, 18, 355-63.
4. Dellapasqua S, Bagnardi V, Bertolini F, et al (2012). Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast, 21, 309-13
5. Gibson TB (2006). Polymorphisms in the thymidylate synthase gene predict response to 5-fluorouracil therapy in colorectal cancer. Clin Colorectal Cancer, 5, 321-3.
6. Hoffbrand AV, Waters AH (1972). Observations on the biochemical basis of megaloblastic anaemia. Br J Haematol, 23, 109-18.
7. Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001). A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer, 85, 827-30.
8. Inanc M, Duran AO, Karaca H, et al (2014). Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. Asian Pac J Cancer Prev, 15, 253-6.
9. Ishikawa T, Fukase Y, Yamamoto T, Sekiguchi F, Ishitsuka H (1998a) Antitumor activities of a novel fluoropyrimidine, N 4-pentoxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull, 21, 713-7.
10. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998b). Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res, 58, 685-90.
11. Karvellas CJ, Sawyer M, Hamilton M, Mackey JR (2004). Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol, 27, 364-8.
12. Kurt M, Aksoy S, Hayran M, Gullu I, Guler N (2006). Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients? Acta Oncol, 45, 625-6.
13. Kurt M, Aksoy S, Hayran M, Gullu I, Guler N (2009). Retrospective analysis of capecitabine monotherapy in patients with metastatic breast cancer: a single center experience. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, 19, 9-17.
14. th edn 770-771.
15. Miwa M, Ura M, Nishida M, et al (1998). Design of novel oral fluoropyrimidine carbamate, capecitabine, which generates 5- fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 34, 1274-81.
16. Nutley NJ (2003). Xeloda (capecitabine) (product information) Roche Pharmaceuticals.
17. Pierga JY, Fumoleau P, Brewer Y, et al (2004). Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat, 88, 117-29.
18. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al (2001). Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J, 1, 65-70.
19. Schuller J, Cassidy J, Dumont E, et al (2000). Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol, 45, 291-7.
20. Scott JM, Weir DG (1980). Drug-induced megaloblastic change. Clin Hematol, 9, 587-606.
21. Takebayashi Y, Akiyama S, Akiba S, et al (1996). Clinicopathologic and prognostic significance of an angiogenetic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst, 88, 1110-7.
22. Wenzel C, Mader RM, Steger GG, et al (2003). Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies. Anti-Cancer Drugs, 14, 119-23.